Abstract
Serum antimullerian hormone (AMH) is frequently used to predict a woman’s response to ovarian stimulation in assisted reproductive technology (ART). However, it has historically shown weak predictability for outcomes per embryo transfer (i.e. pregnancy and live birth rate) as traditionally reported by The Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SARTCORS) prior to 2014. We hypothesized that the association of AMH with ART cumulative live birth rate (CLBR) per cycle start as reported from 2014 onward by SARTCORS may be more informative as CLBR accounts for the entire embryo cohort (fresh and frozen) that are created and linked to a single identified index retrieval.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
